PET studies of net blood-brain clearance of FDOPA to human brain: Age-dependent decline of [18F]fluorodopamine storage capacity

Journal of Cerebral Blood Flow and Metabolism

Volumn 25, Issue 7, 2005, Pages 807-819

  Kumakura, Yoshitaka ^a,b   Vernaleken, Ingo ^c   Gründer, Gerhard ^d   Bartenstein, Peter ^c   Gjedde, Albert ^a,b   Gumming, Paul ^a,b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b Center for Functionally Integrative Neuroscience   (Denmark)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

^d UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

18F fluorodopa; Compartmental analysis; Net influx; Parametric mapping; PET

Indexed keywords

3 O METHYL 6 FLUORODOPA; 6 FLUORODOPA F 18; 6 FLUORODOPAMINE; DOPA; DRUG METABOLITE; UNCLASSIFIED DRUG;

ADULT; AGE; AGED; ARTICLE; BLOOD BRAIN BARRIER; BRAIN MAPPING; CALCULATION; CAUDATE NUCLEUS; CLINICAL ARTICLE; COMPARATIVE STUDY; COMPARTMENT MODEL; CONTROLLED STUDY; DECARBOXYLATION; DIFFUSION COEFFICIENT; DISTRIBUTION VOLUME; DRUG CLEARANCE; DRUG DIFFUSION; FEMALE; HUMAN; HUMAN TISSUE; INNERVATION; MALE; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; SENSITIVITY AND SPECIFICITY; STORAGE;

ADULT; AGING; BRAIN; DIFFUSION; DIHYDROXYPHENYLALANINE; FLUORINE RADIOISOTOPES; HUMANS; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY;

EID: 21344464929     PISSN: 0271678X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jcbfm.9600079     Document Type: Article

References (65)

1. Bhatt MH, Snow BJ, Martin WR, Pate BD, Ruth TJ, Calne DB (1991) Positron emission tomography suggests that the rate of progression of idiopathic parkinsonism is slow. Ann Neurol 29:673-7
2. Bonuccelli U, Piccini P, Del Dotto P, Rossi G, Corsini GU, Muratorio A (1993) Apomorphine test for dopaminergic responsiveness: a dose assessment study. Mov Disord 8:158-64
3. 18F]-6-fluorodopa during positron emission tomography: elimination and metabolism in carbidopa treated subjects. Life Sci 39: 2243-2252
4. Cabello CR, Thune JJ, Pakkenberg H, Pakkenberg B (2002) Ageing of substantia nigra in humans: cell loss may be compensated by hypertrophy. Neuropathol Appl Neurobiol 28:282-91
5. Collins DL, Zijdenbos AP, Kollokian V, Sled JG, Kabani NJ, Holmes CJ, Evans AC (1998) Design and construction of a realistic digital brain phantom. IEEE Trans Med Imaging 17:463-8
6. 18F]fluoro-L-3,4-dihydroxyphenylalanine in the hooded rat. J Neurochem 48:601-8
7. 18F]-6-fluorodopa in the hooded rat following inhibition of catechol-O-methyltransferase with U-0521. Biochem Pharmacol 36:2527-31
8. 18F-fluorodopa in the hooded rat. Biochem Pharmacol 37:247-50
9. 18F]Fdopa) in humans. J Cereb Blood Flow Metab 13:668-75
10. 18F]DOPA) metabolism in the rat. J Neurochem 63:1675-82
11. Cumming P, Kuwabara H, Ase A, Gjedde A (1995) Regulation of DOPA decarboxylase activity in brain of living rat. J Neurochem 65:1381-90
12. Cumming P, Gjedde A, Reith J (1997) Controversies arising from recent FDOPA articles [Letter]. J Nucl Med 38:1267-9
13. Cumming P, Hermansen F, Gjedde A (1999) Cerebral dopamine concentrations during levodopa treatment [Letter]. Neurology 53:1374
14. Cumming P, Gjedde A (1998) Compartmental analysis of dopa decarboxylation in living brain from dynamic positron emission tomograms. Synapse 29:37-61
15. Cumming P, Munk OL, Doudet D (2001) Loss of metabolites from monkey striatum during PET with FDOPA. Synapse 41:212-8
16. 18F-DOPA metabolism in the immature pig brain studied by positron emission tomography. Synapse 33:247-58
17. 18F]fluorodopamine in vivo. J Neurosci Met 76:157-65
18. Dhawan V, Ishikawa T, Patlak C, Chaly T, Robeson W, Belakhef A, Margouleff C, Mandel F, Eidelberg D (1996) Combined FDOPA and 3OMFD PET studies in Parkinson's disease. J Nucl Med 37:209-16
19. Dhawan V, Ishikawa T, Patlak C, Eidelberg D (1997) Controversies arising from recent FDOPA articles [Letter]. J Nucl Med 38:1270-1
20. de la Fuente-Fernández R, Pal PK, Vingerhoets FJ, Kishore A, Schulzer M, Mak EK, Ruth TJ, Snow BJ, Calne DB, Stoessl AJ (2000) Evidence for impaired presynaptic dopamine function in parkinsonian patients with motor fluctuations. J Neural Transm 107:49-57
21. Doudet DJ, Chan GL, Holden JE, Morrison KS, Wyatt RJ, Ruth TJ (1997) Effects of catechol-O-methyltransferase inhibition on the rates of uptake and reversibility of 6-fluoro-L-Dopa trapping in MPTP-induced parkinsonism in monkeys. Neuropharmacology 36:363-71
22. 18F]Fluoro-L-DOPA PET studies of the turnover of dopamine in MPTP-induced parkinsonism in monkeys. Synapse 29:225-32
23. 18F]6-fluoro-L-dopa metabolites in non-human primate: Implications for the kinetics of therapeutic L-DOPA. Frontiers Biosci 9:505-12
24. Garnett ES, Firnau G, Nahmias C (1983) Dopamine visualized in the basal ganglia of living man. Nature 305:137-8
25. Gillings NM, Bender D, Falborg L, Marthi K, Munk OL, Cumming P (2001) Kinetics of the metabolism of four PET radioligands in living minipigs. Nucl Med Biol 28:97-104
26. Gjedde A (1981) High- and low-affinity transport of D-glucose from blood to brain. J Neurochem 36: 1463-1471
27. Gjedde A (1982) Calculation of cerebral glucose phosphorylation from brain uptake of glucose analogs in vivo: a reexamination. Brain Res 257:237-74
28. Gjedde A (1988) Exchange diffusion of large neutral amino acids between blood and brain. In: Peptide and amino acid transport mechanisms in the central nervous system (Rakic L et al, eds) New York: Stockton Press, 209-17
29. Gjedde A, Reith J, Dyve S, Léger G, Guttman M, Diksic M, Evans A, Kuwabara H (1991) Dopa decarboxylase activity of the living human brain. Proc Natl Acad Sci USA 88:2721-5
30. Gjedde A, Léger GC, Cumming P, Yasuhara Y, Evans AC, Guttman M, Kuwabara H (1993) Striatal L-dopa decarboxylase activity in Parkinson's disease in vivo: implications for the regulation of dopamine synthesis. J Neurochem 61:1538-41
31. 18F] fluoro-L-dopa in rhesus monkey. Nucl Med Biol 22:921-7
32. Holden JE, Doudet D, Endres CJ, Chan GL-Y, Morrison KS, Vingerhoets FJG, Snow BJ, Pate BD, Sossi V, Buckley KR, Ruth TJ (1997) Graphical analysis of 6-fluoro-L-dopa trapping: Effect of inhibition of catechol-O-methyltransferase. J Nucl Med 38:1568-74
33. Home MK, Cheng CH, Wooten GF (1984) The cerebral metabolism of L-dihydroxyphenylalanine: an autoradiographic and biochemical study. Pharmacology 28:12-26
34. 18F]fluoro-L-dopa metabolism in living human brain: a comparison of six analytical methods. J Cereb Blood Flow Metab 13:57-69
35. 18F]fluoro-dopa in human positron emission tomographic studies. J Cereb Blood Flow Metab 11:898-913
36. Ishikawa T, Dhawan V, Chaly T, Margouleff C, Robeson W, Dahl JR, Mandel F, Spetsieris P, Eidelberg D (1996a) Clinical significance of striatal DOPA decarboxylase activity in Parkinson's disease. J Nucl Med 37:216-22
37. Ishikawa T, Dhawan V, Chaly T, Robeson W, Belakhlef A, Mandel F, Dahl R, Margouleff C, Eidelberg D (1996b) Fluorodopa positron emission tomography with an inhibitor of catechol-O-methyltransferase: effect of the plasma 3-O-methyldopa fraction on data analysis. J Cereb Blood Flow Metab 16:854-63
38. 18F]fluorodopa uptake in early Parkinson's disease: sex differences in the prefrontal cortex. Brain 124:1125-30
39. 18F]fluorodopa to brain of normal volunteers and patients with Parkinson's disease: effect of levodopa. Acta Neurol Scand 110:188-95
40. 18F]fluorodeoxyglucose. J Cereb Blood Flow Metabol 10:180-9
41. Kuwabara H, Gjedde A (1991) Measurements of glucose phosphorylation with FGD phosphate and PET are not reduced by dephosphorylation of FDG-6-phosphate. J Nucl Med 32:692-8
42. 18F]fluoro-DOPA and positron emission tomography: Error analysis and applications to normal subjects. J Cereb Blood Flow Metab 13:43-56
43. Lee CS, Samii A, Sossi V, Ruth TJ, Schulzer M, Holden JE, Wudel J, Pal PK, de la Fuente-Fernández R, Gaine DB, Stoessl AJ (2000) In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann Neurol 47:493-503
44. 18F]fluorodopa: implications for compartmental modelling and clinical usefulness. Synapse 30:351-61
45. Martin WR, Palmer MR, Patlak CS, Calne DB (1989) Nigrostriatal function in humans studied with positron emission tomography. Ann Neurol 26:535-42
46. McGeer PL, McGeer EG, Suzuki JS (1977) Aging and extrapyramidal function. Arch Neurol 34:33-5
47. 18F]fluorodopa metabolism in monkeys and humans: biochemical parameters for the formulation of tracer kinetic models with positron emission tomography. J Cereb Blood Flow Metab 11:890-7
48. Patlak CS, Blasberg RG, Fenstermacher JD (1983) Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab 3:1-7
49. Patlak CS, Blasberg RG (1985) Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations. J Cereb Blood Flow Metab 5:584-90
50. 18F]fluoro-L-DOPA uptake in rhesus monkey: pharmacological influence of aromatic amino acid decarboxylase (AAAD) and catechol-O-methyltransferase (COMT) inhibition. Brain Res 767:45-54
51. 18F]dopa-PET study. Brain 122:1637-50
52. Reilhac A, Sechet S, Boileau I, Gunn R, Evans A, Dagher A (2003) Motion correction for PET ligand imaging. NeuroImage 19; Part 2 of 2 parts, S46 (poster #927). PROGRAM. Human Brain Mapping 2003, New York, June 18-22, 2003.
53. 18F]fluoro-L-dopa studied with PET in normal control and Parkinson's disease subjects. Synapse 37:81-9
54. 18F]fluorodopa utilization after COMT inhibition with entacapone studied with PET in advanced Parkinson's disease. J Neural Transm Park Dis Dement Sect 10:91-106
55. 18F]fluorodopa accumulation after combined inhibition of peripheral catechol-O-methyl- transferase and monoamine oxidase type B: differing response in relation to presynaptic dopaminergic dysfunction. Synapse 27:336-46
56. Snow BJ, Peppard RF, Guttman M, Okada J, Martin WR, Steele J, Eisen A, Carr G, Schoenberg B, Calne D (1990) Positron emission tomographic scanning demonstrates a presynaptic dopaminergic lesion in Lytico-Bodig. The amyotrophic lateral sclerosis-parkinsonism-dementia complex of Guam. Arch Neurol 47:870-4
57. Sossi V, Doudet DJ, Holden JE (2001) A reversible tracer analysis approach to the study of effective dopamine turnover. J Cereb Blood Flow Metab 21:469-76
58. Sossi V, de La Fuente-Fernández R, Holden JE, Doudet DJ, McKenzie J, Stoessl AJ, Ruth TJ (2002) Increase in dopamine turnover occurs early in Parkinson's disease: evidence from a new modeling approach to PET 18 F-fluorodopa data. J Cereb Blood Flow Metab 22:232-9
59. 18F] fluorodopa plasma input uptake rate constant Ki. J Cereb Blood Flow Metab 23:301-9
60. Sossi V, de la Funente-Fernández R, Holden JE, Schulzer M, Ruth TJ, Stoessl J (2004) Changes of dopamine turnover in the progression of Parkinson's disease as measured by positron emission tomography: their relation to disease-compensatory mechanisms. J Cereb Blood Flow Metab 24:869-76
61. Taylor SF, Koeppe RA, Tandon R, Zubieta JK, Frey KA (2000) In vivo measurement of the vesicular monoamine transporter in schizophrenia. Neuropsychopharmacology 23:667-75
62. Vingerhoets FJ, Schulzer M, Ruth TJ, Holden JE, Snow BJ (1996) Reproducibility and discriminating ability of fluorine-18-6-fluoro-L-Dopa PET in Parkinson's disease. J Nucl Med 37:421-6
63. 18F]fluoro-O-methyl-L-dopa in the human brain. J Cereb Blood Flow Metab 14:664-70
64. Woods RP, Cherry SR, Mazziotta JC (1992) Rapid automated algorithm for aligning and reslicing PET images. J Comput Assist Tomogr 16:620-33
65. 18F]fluoro- L-DOPA. Biochem Pharmacol 62:1409-15